Volume 1.18 | May 21

Prostate Cell News 1.18, May 21, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Cadherin-11 Increases Migration and Invasion of Prostate Cancer Cells and Enhances their Interaction with Osteoblasts
Here, researchers show that expression of cadherin-11 in cadherin-11-negative C4-2B4 cells increases their spreading and intercalation into an osteoblast layer and also stimulates C4-2B4 cell migration and invasiveness. [Cancer Res]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies



Gene Fusions May Be the ‘Smoking Gun’ in Prostate Cancer Development: Study
Prostate cancer treatments that target the hormone androgen and its receptor may be going after the wrong source, according to a new study. [Press release from the University of Michigan Comprehensive Cancer Center discussing online prepublication in Cancer Cell]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
These findings provide a working model in which TMPRSS2-ERG plays a critical role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program. [Cancer Cell]

Androgen Receptor Requires JunD as a Coactivator to Switch on an Oxidative Stress Generation Pathway in Prostate Cancer Cells
Here, researchers present coimmunoprecipitation and Gaussia luciferase reconstitution assay data that show that JunD forms a complex with androgen-activated androgen receptor in situ. [Cancer Res]

Epigenetic Mechanisms of Promigratory Chemokine CXCL14 Regulation in Human Prostate Cancer Cells
In this study, researchers investigated the mechanisms of loss of CXCL14 in prostate cancer cells. [Cancer Res]

The Multikinase Inhibitor Sorafenib Induces Caspase-Dependent Apoptosis in PC-3 Prostate Cancer Cells
The present study investigated the effects of the multikinase inhibitor sorafenib on androgen-independent cancer cells viability and intracellular signaling. [Asian J Androl]

Antagonism of Estrogen-Mediated Cell Proliferation by Raloxifene in Prevention of Ageing-Related Prostatic Hyperplasia
Researchers evaluated the effect of estrogen antagonist, raloxifene, on the prevention and treatment of benign prostatic hyperplasia (BPH) by investigating its effect on the proliferation of two different prostate cell lines: a stromal cell line, WPMY-1, and a benign prostatic hyperplasia epithelial cell line, BPH-1. [Asian J Androl]

Osteoblasts Can Stimulate Prostate Cancer Growth and Transcriptionally Down-Regulate PSA Expression in Cell Line Models
The purpose of this study was to investigate the effect of bone environment on cellular proliferation, mature prostate-specific antigen (PSA) production and secretion, and PSA transcriptional regulation of prostate cancer cells. [Urol Oncol]


Results From a Phase I Clinical Study of the Novel Ii-Key/HER-2/Neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Researchers conducted the first phase I trial of an Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine (AE37) with recombinant GM-CSF as adjuvant in patients with HER-2/neu+ prostate cancer. [Clin Cancer Res]

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Researchers conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer. [Clin Cancer Res]

Susceptibility Loci Associated with Prostate Cancer Progression and Mortality
Researchers investigated associations between 29 single nucleotide polymorphisms and biochemical recurrence, castration-resistant metastasis, and prostate cancer-specific survival. [Clin Cancer Res]


Generex Biotechnology Announces Publication of Novel Immunotherapeutic Cancer Vaccine Results in Patients
Generex Biotechnology Corporation announced publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. [Generex Biotechnology Corporation Press Release]

Report on Phase II Clinical Study of Marshall Edwards’ Phenoxodiol in Prostate Cancer to be Presented at ASCO
An abstract titled “A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes” by Dr Kevin Kelly at the Yale School of Medicine Department of Medical Oncology, is now available. [Marshall Edwards, Inc. Press Release]

Chronix to Present Data at ASCO that Could Revolutionize the Diagnostic Paradigm for Cancer
Chronix Biomedical reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. [Chronix Biomedical Press Release]

GTx Announces Upcoming ASCO Presentations of Additional Study Results from Clinical Trials Evaluating Ostarine(TM) for Cancer Cachexia and Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on ADT
GTx Inc. announced that additional study results from clinical trials evaluating Ostarine(TM) (GTx-024) for the treatment of cancer cachexia and toremifene 80 mg for the reduction of fractures in men with prostate cancer on androgen deprivation therapy (ADT) will be presented. [GTx Inc. Press Release]


Personal Gene-Testing Companies Need U.S. Clearance, FDA Says
Gene-test kits that promise to tell consumers their risk of Alzheimer’s disease, breast cancer and numerous illnesses must be approved by regulators whether the tests are sold online or in stores, a U.S. official said. [Food and Drug Administration, United States]

NIH Starts to Flesh out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started – once the program has a budget. [National Institutes of Health, United States]

Statement by HHS Secretary Kathleen Sebelius and NIH Director Francis Collins Regarding the President’s Intent to Appoint Dr. Harold Varmus as Director of the National Institute of Cancer at the National Institutes of Health [National Institutes of Health, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089) [National Institutes of Health, United States]

Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]


American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us